Perylenequinone derivatives and uses thereof

The present invention relates to compounds which are perylenequinone derivatives, their stereoisomers and atropisomers. These compounds can be particularly useful as photosensitizers or sononsensitizers in photodynamic or sonodynamic therapy. The invention also relates to various methods for using these compounds in photodynamic and/or sonodynamic therapy. The compounds also are useful as therapeutic agents for treating various hyperproliferative disorders.

REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed. 2. (canceled)3. (canceled)4. (canceled)6. A method of treating a mitochondrial disorder claim 5 , modulating one or more energy biomarkers claim 5 , normalizing one or more energy biomarkers claim 5 , or enhancing one or more energy biomarkers claim 5 , comprising administering to a subject a therapeutically effective amount or effective amount of one or more compounds of .13. A method of treating a mitochondrial disorder claim 12 , modulating one or more energy biomarkers claim 12 , normalizing one or more energy biomarkers claim 12 , or enhancing one or more energy biomarkers claim 12 , by administering to a subject a therapeutically effective amount or effective amount of one or more compounds of .16. A method of treating a mitochondrial disorder claim 15 , modulating one or more energy biomarkers claim 15 , normalizing one or more energy biomarkers claim 15 , or enhancing one or more energy biomarkers claim 15 , by administering to a subject a therapeutically effective amount or effective amount of one or more compounds of .18. (canceled)19. The method of claim 6 , wherein the mitochondrial disorder is selected from the group consisting of inherited mitochondrial diseases; Myoclonic Epilepsy with Ragged Red Fibers (MERRF); Mitochondrial Myopathy claim 6 , Encephalopathy claim 6 , Lactacidosis ...

SMALL MOLECULES FOR IMMUNOGENIC TREATMENT OF CANCER

The present invention relates to new compounds for immunogenic treatment of cancer. The compounds can be administered as a single agent or in combination with an anticancer drug including modulators of other immune pathways, especially immune checkpoint inhibitors that target CTLA-4, PD-1, and PD-L1 proteins. The compounds can produce neoantigens through irreversible protein binding in cancer cells and generate immune response. 3. The compound of claim 1 , wherein said targeting moiety (TM) is an antibody claim 1 , a folate receptor binding moiety claim 1 , a peptide claim 1 , a nanoparticle based delivery vehicle claim 1 , a selective tyrosine kinase inhibitor claim 1 , or an Hsp90 inhibitor.4. The compound of claim 1 , wherein said targeting moiety (TM) is a targeting moiety connected through a nitrogen atom (—N(TM)) or an oxygen atom (—O(TM)) of the targeting moiety.1158-. (canceled)59. The compound of claim 1 , wherein said compound isN-(2-((3,4-dimethoxyphenyl)thio)ethyl)propionamide;N-[2-(3,4-dihydroxyphenyl)sulfanylethyl]propenamide;N-[2-(2,5-dihydroxyphenyl)sulfanylethyl]propenamide;N-[2-(2,3-dihydroxyphenyl)sulfanylethyl]propenamide;4-(2-aminoethylsulfanyl)benzene-1,2-diol;N-[2-(3,4-dimethoxyphenyl) sulfanylethyl]heptanamide;N-[2-(3,4-dihydroxyphenyl)sulfanylethyl]heptanamide;N-[2-(3,4-dihydroxyphenyl)sulfanylethyl]undecanamide;N-[2-(3,4-dimethoxyphenyl)sulfanylethyl]undecanamide;N-[2-(3,4-dihydroxyphenyl)sulfanylethyl]undecanamide;N-[2-(3,4-dimethoxyphenyl)sulfanylethyl]undecanamide;N-[2-(3,4-dihydroxyphenyl)sulfanylethyl]pentanamide;3-(5,5-difluoro-1,3-dimethyl-dipyrrolo[3,1-c:2′,1′-g][1,3,2]diazaborinin-4-ium-7-yl)-N-[2-(3,4-dihydroxyphenyl)sulfanylethyl]propenamide;N-[2-(3,4-dihydroxyphenyl) sulfanylethyl]cyclopentanecarboxamide;3-pentadecylbenzene-1,2-diol;(4Z)-4-[(7-chloro-4-quinolyl)imino]-2-(diethylaminomethyl)cyclohexa-2,5-dien-1-one; or3-[(Z)-pentadec-10-enyl]benzene-1,2-diol.60. The compound of claim 1 , wherein said conjugate is an antibody drug ...

Treatment of pervasive developmental disorders with redox-active therapeutics

Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

TOCOPHEROL AND TOCOPHERYL QUINONE DERIVATIVES AS CORRECTORS OF LYSOSOMAL STORAGE DISORDERS

The subject invention relates to improved tocopheryl quinine derivatives and tocopherol derivatives having improved pharmacokinetics in vivo that can, in some embodiments, be useful in the treatment of Lysosomal Storage Disorder, restoration of normal mitochondrial ATP production, modulation of intracellular calcium ion concentration and other treatments or therapies. The tocopheryl quinone derivatives and tocopherol derivatives have side chains that have terminally halogenated carbon atoms. 221-. (canceled) This application claims the benefit of U.S. Provisional Application No. 61/727,296 filed on Nov. 16, 2012, the entire disclosure of which is hereby incorporated by reference.The instant application was made with government support; the government has certain rights in this invention.Each of the applications and patents cited in this text, as well as each document or reference cited in each of the applications and patents (including during the prosecution of each issued patent: “application cited documents”), and each of the PCT and foreign applications or patents corresponding to and/or claiming priority from any of these applications and patents, and each of the documents cited or referenced in each of the application cited documents, are hereby expressly incorporated herein by reference and may be employed in the practice of the invention. More generally, documents or references are cited in this text, either in a Reference List before the claims, or in the text itself; and, each of these documents or references (“herein cited references”), as well as each document or reference cited in each of the herein cited references (including any manufacturer's specifications, instructions, etc.), is hereby expressly incorporated herein by reference.The subject invention relates to novel tocopheryl quinone derivatives and tocopherol derivatives having improved pharmacokinetics in vivo that can, in some embodiments, be useful in the treatment of Lysosomal Storage ...

Concerted processes for forming 1,2,4-trihydroxybenzene from hydroquinone

Flow batteries incorporating an active material with one or more catecholate ligands can have a number of desirable operating features. Commercial syntheses of catechol produce significant quantities of hydroquinone as a byproduct, which presently has limited value in the battery industry and can represent a significant waste disposal issue at industrial production scales. Using a concerted, high-yield process, low-value hydroquinone can be transformed into high-value 1,2,4-trihydroxybenzene, which can be a desirable ligand for active materials of relevance in the flow battery industry. Methods for forming 1,2,4-trihydroxybenzene can include: oxidizing hydroquinone in a first reaction to form p-benzoquinone, converting the p-benzoquinone in a second reaction to form 1,2,4-triacetoxybenzene, deacetylating the 1,2,4-triacetoxybenzene in a third reaction to form 1,2,4-trihydroxybenzene, and isolating the 1,2,4-trihydroxybenzene after performing the first reaction, the second reaction and the third reaction consecutively.

ANTI-MALARIAL COMPOUNDS FROM MARINE NATURAL PRODUCTS

Novel compositions and methods for the treatment and prevention of malaria are disclosed herein. 3P. falciparum. The composition of claim 1 , wherein the compound comprises a ratio of a NIH 3T3 ICμm value to a ICμm value of at least 9:1.4. A pharmaceutical composition comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'an effective amount of the composition of ; and'}a pharmaceutically acceptable carrier.5. A pharmaceutical composition comprising:{'claim-ref': {'@idref': 'CLM-00002', 'claim 2'}, 'an effective amount of the composition of ; and'}a pharmaceutically acceptable carrier.6. A method for treating or preventing malaria in a subject comprising administering to a subject in need thereof an effective amount of the composition of .7. The method of claim 6 , wherein composition further comprises a pharmaceutically acceptable carrier.8. The method of claim 6 , further comprising administering a conjunctive anti-malarial agent to the subject.9P. falciparum. The method of claim 6 , wherein the compound of the composition comprises a ratio of a NIH 3T3 ICμm value to a ICμm value of at least 9:1.10. A method for treating or preventing malaria in a subject comprising administering to a subject in need thereof an effective amount of the composition of .11. The method of claim 10 , wherein composition further comprises a pharmaceutically acceptable carrier.12. The method of claim 10 , further comprising administering a conjunctive anti-malarial agent to the subject.13. A method for treating a condition in a subject in need claim 1 , the method comprising administering to the subject an effective amount of the composition of claim 1 , wherein the condition comprises of a symptom of malaria.14. The method of claim 13 , wherein composition further comprises a pharmaceutically acceptable carrier.15. The method of claim 13 , further comprising administering a conjunctive anti-malarial agent to the subject.17F. Plasmodium. A method of treating malaria by killing or ...

TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS

Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD—not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein. 113-. (canceled)1731-. (canceled)32. The method of claim 14 , wherein the bonds indicated with a dashed line are all single bonds.33. The method of claim 14 , wherein the bonds indicated with a dashed line are all double bonds.34. The method of claim 16 , wherein the bonds indicated with a dashed line are all single bonds.35. The method of claim 16 , wherein the bonds indicated with a dashed line are all double bonds.36. The method of claim 14 , wherein R claim 14 , R claim 14 , and Rare independently selected from the group consisting of H claim 14 , (C-C)alkyl claim 14 , and (C-C)alkoxy.37. The method of claim 14 , wherein R claim 14 , R claim 14 , and Rare independently selected from (C-C)alkyl.38. The method of claim 14 , wherein R claim 14 , R claim 14 , and Rare methyl.39. The method of claim 14 , wherein at least one of R claim 14 , R claim 14 , and Ris not methyl.40. The method of claim 14 , wherein Rand Rare methoxy claim 14 , and Ris methyl.41. The method of claim 32 , wherein the method is for treating the PDD claim 32 , wherein the PDD is autistic spectrum disorder (ASD).42. The method according to claim 33 , wherein the method is for treating the PDD claim 33 , wherein the PDD is autistic spectrum disorder (ASD).43. The method of claim 34 , wherein the method is for treating the PDD claim 34 , wherein the PDD is autistic spectrum disorder (ASD).44. The method according to claim 35 , wherein the method is for treating the PDD claim 35 , wherein the PDD is autistic spectrum disorder (ASD).45. The method according to claim 32 , wherein the method is ...

Method for production of thymoquinone

A method of producing thymoquinone and/or thymohydroquinone in Monarda by growing Monarda with elevated levels of carvacrol and/or thymol in the fresh plant tissue and vigorous growth, harvesting the Monarda , leaving the Monarda to senensce in the presence of oxygen and extracting the thymoquinone and/or thymohydroquinone from the senesced tissue.

Non-Aqueous Electrolyte Solution for Lithium Secondary Battery and Lithium Secondary Battery Including the Same

A non-aqueous electrolyte solution for a lithium secondary battery and a lithium secondary battery including the same are disclosed herein. In some embodiments, a non-aqueous electrolyte solution for a lithium secondary battery, includes a lithium salt, an organic solvent, and an additive, wherein the additive includes a compound represented by Formula 1.

Treatment of pervasive developmental disorders with redox-active therapeutics

Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

Nanomaterial, preparation method thereof, and semiconductor device

A nanomaterial includes a ZnO nanocrystal and a surface ligand bonded to the ZnO nanocrystal. The surface ligand has a structure ofR1, R2, and R3 are independently selected from at least one of an alkyl group, an alkoxy group, a hydroxyalkoxy group, a hydroxyl group, or a hydrogen atom. R4 is selected from a hydrocarbon group having a carbon number of 5 to 60. A carbon number of the alkyl group ranges from 1 to 5. A carbon number of the alkoxy group ranges from 1 to 5. A carbon number of the hydroxyalkoxy group ranges from 1 to 5.

PHOTODYNAMIC DIAGNOSIS, FORMULATIONS USABLE AS PHOTOSENSITIZERS FOR THIS PURPOSE, METHOD FOR THE PRODUCTION AND USE THEREOF

In the early detection of cancer, in particular bladder cancer, a photodynamic diagnosis uses, as a photosensitizer, a formulation that contains sodium hypericinate that is bonded to polyvinylpyrrolidone or complexed with polyvinylpyrrolidone. 1. A formulation for photodynamic diagnosis of tumors , containing hypericin that is bonded or complexed to a polymeric complexing agent , wherein the hypericin is present as a salt.2. The formulation according to claim 1 , wherein the complexing agent is a polyethylene glycol or a poly-N-vinyl amide.3. The formulation according to claim 2 , wherein poly-N-vinyl amide is a polyvinylpyrrolidone (PVP) of various degrees of polymerization and cross-linking.4. The formulation according to claim 3 , wherein the polyvinylpyrrolidone is PVP k17 claim 3 , PVP k25 claim 3 , or PVP k30.5. The formulation according to claim 1 , wherein the hypericin salt is an alkali metal salt claim 1 , a potassium salt or a sodium salt.6. A method for the production of the formulation according to claim 1 , comprising:bonding or complexing the hypericin salt to a polyethylene glycol or to a poly-N-vinyl amide, or polyvinylpyrrolidone (PVP).7. The method according to claim 6 , wherein the complexing is performed in aqueous claim 6 , optionally buffered claim 6 , solution.8. The method according to claim 6 , wherein the formulation is prepared for intravenous claim 6 , intracavity claim 6 , inhalative claim 6 , oral claim 6 , intraperitoneal and topical administration claim 6 , in hydrophilic or hydrophobic vehicles claim 6 , or in the form of a solution claim 6 , a cream claim 6 , a gel claim 6 , an aerosol claim 6 , emulsions or as a patch.9. The method according to claim 7 , wherein the aqueous solution is decanted into injection flasks and freeze-dried.10. A method for preparing a lyophilizate from which a photosensitizer for photodynamic diagnosis of tumors may be obtained claim 7 , comprising the following successive steps:a) preparing a solution ...

TOCOPHEROL AND TOCOPHERYL QUINONE DERIVATIVES AS CORRECTORS OF LYSOSOMAL STORAGE DISORDERS

The subject invention relates to improved tocopheryl quinone derivatives and tocopherol derivatives having improved pharmacokinetics in vivo that can, in some embodiments, be useful in the treatment of Lysosomal Storage Disorders, restoration of normal mitochondrial ATP production, modulation of intracellular calcium ion concentration and other treatments or therapies. The tocopheryl quinone derivatives and tocopherol derivatives have side chains that have terminally halogenated carbon atoms. 7. The method of claim 5 , further comprising the step of administering to said patient a cyclodextrin.13. A pharmaceutical composition comprising the tocopherol derivative of ; anda pharmaceutically acceptable vehicle.16. A method for treating a lysosomal storage disorder comprising administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of ;{'sub': 8', '1', '5, 'wherein R=lower alkyl having C-C.'}19. The method of claim 16 , wherein the treatment with the composition comprising the tocopherol derivative substantially increases Ca influx to the cells and/or cholesterol exocytosis from the cells of the patient.20. The method of claim 16 , wherein the lysosomal storage disorder is selected from the group consisting of Niemann Pick Type C (NPC) claim 16 , Wolman claim 16 , Niemann Pick Type A claim 16 , Farber claim 16 , Tay-Saches claim 16 , MSIIIB and CLN2 (Batten) diseases.21. The method of claim 16 , further comprising the step of administering to said patient a therapeutically effective amount of a cyclodextrin. This application claims the benefit of U.S. Provisional Application No. 61/727,296 filed on Nov. 16, 2012, the entire disclosure of which is hereby incorporated by reference.The instant application was made with government support; the government has certain rights in this invention.Each of the applications and patents cited in this text, as well as each document or reference cited in each of the applications ...

METHOD FOR PRODUCING 2,3,5-TRIMETHYL BENZOQUINONE BY OXIDATION OF 2,3,6-TRIMETHYLPHENOL

The invention relates to a method for producing 2,3,5-trimethyl benzoquinone or a compound containing 2,3,5-trimethyl benzoquinone, the method comprising the following steps: Oxidation of 2,3,6-trimethylphenol with oxygen or an oxygen-containing gas in a two- or multi-phase reaction medium in the presence of a catalyst or catalyst system containing at least one copper (II)-halide to a mixture containing 2,3,5-trimethyl benzoquinone, characterized in that the reaction medium contains water and at least one secondary aliphatic acyclic alcohol having 6 or more, preferably 7 or more, carbon atoms. 115-. (canceled)16. A mixture comprising 2 ,3 ,5-trimethylbenzoquinone which has a copper content of less than 240 mg/kg.17. The mixture as claimed in claim 16 , wherein the mixture has a lithium content of less than 0.3 g/100 g.18. The mixture as claimed in claim 16 , wherein the mixture has a chlorine content of less than 0.5 g/100 g.19. The mixture as claimed in claim 16 , wherein the mixture has a copper content of less than 220 mg/kg.20. The mixture as claimed in claim 16 , wherein the mixture has a copper content from 210 to 220 mg/kg.21. The mixture as claimed in claim 17 , wherein the mixture has a copper content from 210 to 220 mg/kg.22. The mixture as claimed in claim 16 , wherein the mixture has a chlorine content of less than 0.42 g/100 g.23. The mixture as claimed in claim 16 , wherein the mixture has a chlorine content of from 0.26 g/100 g to 0.42 g/100 g.24. The mixture as claimed in claim 21 , wherein the mixture has a chlorine content of from 0.26 g/100 g to 0.42 g/100 g.26. The mixture according to claim 25 , wherein the mixture has a chlorine content of less than 0.5 g/100 g.27. The mixture according to claim 25 , wherein the mixture has a lithium content of less than 0.3 g/100 g.28. The mixture according to claim 25 , wherein the mixture has a copper content of less than 240 mg/kg.29. The mixture according to claim 26 , wherein the mixture has a lithium ...

TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS

Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein. 131-. (canceled)37. A composition comprising a compound of and a pharmaceutically acceptable carrier.38. A composition comprising the compound of and a pharmaceutically acceptable carrier.39. A composition comprising the compound of and a pharmaceutically acceptable carrier.40. A composition comprising the compound of and a pharmaceutically acceptable carrier.41. A composition comprising a compound of and a pharmaceutically acceptable carrier.42. A food claim 32 , medical food claim 32 , functional food claim 32 , food supplement claim 32 , or dietary supplement comprising a compound of and a physiologically or nutritionally acceptable carrier claim 32 , adjuvant claim 32 , excipient claim 32 , buffer claim 32 , or diluent.43. A method of reducing a symptom associated with claim 32 , or for treating or suppressing a pervasive developmental disorder (PDD) or attention deficit/hyperactivity disorder (ADHD) in a patient in need of such treatment claim 32 , comprising administering to the patient a therapeutically or physiologically effective amount of a compound of .44. The method of claim 43 , wherein the method is for treating the PDD.45. The method of claim 44 , wherein the PDD is autistic disorder.46. The method according to claim 43 , wherein the method is for treating attention deficit/hyperactivity disorder (ADHD).47. The method according to claim 44 , wherein the PDD is Rett's disorder.48. A method of reducing a symptom associated with claim 36 , or for treating or suppressing a pervasive developmental disorder (PDD) or attention deficit/hyperactivity ...

SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed. 145-. (canceled)47. The compound of claim 46 , wherein R claim 46 , R claim 46 , and Rare independently selected from the group consisting of —H claim 46 , —C-Calkyl claim 46 , —C-Chaloalkyl claim 46 , —C-Calkenyl claim 46 , —C-Chaloalkenyl claim 46 , —C-Calkynyl claim 46 , and —C-Chaloalkynyl claim 46 , and where at least one of R claim 46 , R claim 46 , and Ris independently selected from the group consisting of —C-Calkyl claim 46 , —C-Chaloalkyl claim 46 , —C-Calkenyl claim 46 , —C-Chaloalkenyl claim 46 , —C-Calkynyl claim 46 , and —C-Chaloalkynyl.48. The compound of claim 47 , wherein at least one of R claim 47 , R claim 47 , and Ris independently selected from the group consisting of —C-Calkyl claim 47 , —C-Chaloalkyl claim 47 , —C-Calkenyl claim 47 , —C-Chaloalkenyl claim 47 , —C-Calkynyl claim 47 , and —C-Chaloalkynyl.49. The compound of claim 46 , wherein at least two of R claim 46 , R claim 46 , and Rare independently selected from the group consisting of —C-Calkyl claim 46 , —C-Chaloalkyl claim 46 , —C-Calkenyl claim 46 , —C-Chaloalkenyl claim 46 , —C-Calkynyl claim 46 , and —C-Chaloalkynyl.50. The compound of claim 49 , wherein R claim 49 , R claim 49 , and Rare independently selected from the group consisting of —C-Calkyl claim 49 , —C-Chaloalkyl claim 49 , —C-Calkenyl claim 49 , —C-Chaloalkenyl claim 49 , —C-Calkynyl ...

2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING ALPHA-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS

Disclosed herein are methods of treating or suppressing a disorder selected from the group consisting of α-synucleinopathies, tauopathies, ALS, traumatic brain injury, and ischemic-reperfusion related injuries.ury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: or the hydroquinone form thereof; or a solvate or hydrate thereof. 24-. (canceled)5. The method of claim 1 , wherein α-synuclein aggregation is inhibited.6. (canceled)7. The method of claim 1 , wherein the Parkinson's Disease is genetic.8. The method of claim 1 , wherein the Parkinson's Disease is idiopathic.9. The method of claim 1 , wherein the subject in need thereof has a mutation in glucocerebrosidase (GBA).1016-. (canceled)17. The method of claim 1 , wherein the method is for treating the disorder.18. The method of claim 1 , wherein the method is for suppressing the disorder.19. The method of claim 1 , wherein the compound is administered orally.20. (canceled)21. A polymorph of an anhydrate of 2 claim 1 ,3 claim 1 ,5-trimethyl-6-nonylcyclohexa-2 claim 1 ,5-diene-1 claim 1 ,4-dione claim 1 , wherein a powder X-ray diffraction pattern for the polymorph comprises characteristic peaks at least at the following angular positions claim 1 , wherein the angular positions may vary by ±0.2:4.10 claim 1 , 12.12 claim 1 , and 16.14; wherein the data are obtained with a Cu Kat source claim 1 , a wavelength of 1.540598 Å claim 1 , and a temperature of 23-25° C.2230-. (canceled)31. A composition comprising the polymorph of claim 21 , wherein at least about 95% by mole of the 2 claim 21 ,3 claim 21 ,5-trimethyl-6-nonylcyclohexa-2 claim 21 ,5-diene-1 claim 21 ,4-dione is the polymorph claim 21 , exclusive of any solvents claim 21 , carriers or excipients.3241-. (canceled)42. A pharmaceutical composition prepared with the polymorph of claim 21 , and a pharmaceutically acceptable solvent claim 21 , carrier claim 21 , or excipient.5368-. (canceled)69. ...

Photo-thermally induced polymerization inhibitors for electrophoretic media

An electrophoretic medium that may be incorporated into an electrophoretic display includes a dispersion that may be contained in a plurality of microcapsules or microcells or a polymeric continuous phase. The dispersion may include a non-polar fluid, a plurality of first charged particles; and an inhibitor of photo-thermally induced polymerization that inhibits potential cross-linking between the particles and/or the microcells or polymeric continuous phase. The inhibitor may be a compound having an unsaturated hydrocarbon ring and at least one of a hydroxyl group, a carbonyl group, and a nitroso group. The plurality of microcells or polymeric continuous phase and a coating of the particles may include a polymeric material that includes (meth)acrylates.

HIGH IONIC CONDUCTIVITY RECHARGEABLE SOLID STATE BATTERIES WITH AN ORGANIC ELECTRODE

An improved rechargeable battery may utilize materials that are entirely solid-state. The battery may utilize at least one organic active material for an electrode. The battery may utilize a cathode that comprises quinone(s). An electrolyte of the battery may be an ion-conducting inorganic compound. An anode of the battery may comprise an alkali metal. Further, a carbonyl group of the quinone(s) of the cathode may be reduced into a phenolate and coordinated to an alkali metal ion during discharge and vice versa during charging.

METHOD FOR PRODUCING 2,3,5-TRIMETHYL BENZOQUINONE BY OXIDATION OF 2,3,6-TRIMETHYLPHENOL

The invention relates to a method for producing 2,3,5-trimethyl benzoquinone or a compound containing 2,3,5-trimethyl benzoquinone, the method comprising the following steps: Oxidation of 2,3,6-trimethylphenol with oxygen or an oxygen-containing gas in a two-or multi-phase reaction medium in the presence of a catalyst or catalyst system containing at least one copper (II)-halide to a mixture containing 2,3,5-trimethyl benzoquinone, characterized in that the reaction medium contains water and at least one secondary aliphatic acyclic alcohol having 6 or more, preferably 7 or more, carbon atoms. 115.-. (canceled)16. A process for preparing 2 ,3 ,5-trimethylbenzoquinone or a mixture comprising 2 ,3 ,5-trimethylbenzoquinone , comprising the following step:(i) oxidizing 2,3,6-trimethylphenol to 2,3,5-trimethylbenzoquinone with oxygen or an oxygen-containing gas in a two-phase or multiphase reaction medium in the presence of a catalyst or catalyst system at least comprising a copper(II) halide, to give a mixture comprising 2,3,5-trimethylbenzoquinone,wherein the reaction medium comprises water and at least one secondary aliphatic acyclic alcohol having 6 or more carbon atoms.17. The process according to claim 16 , wherein said at least one secondary aliphatic acyclic alcohol having 7 or more carbon atoms18. The process according to claim 16 , wherein the catalyst or the catalyst system comprises copper (II) chloride.19. The process according to claim 16 , wherein the catalyst or the catalyst system further comprises at least one alkali metal halide.20. The process according to claim 19 , wherein said at least one alkali metal halide is lithium chloride.21. The process according to claim 16 , wherein the reaction medium comprises 3-heptanol.22. The process according to claim 16 , wherein the process is carried out batchwise.23. The process according to claim 16 , wherein the mixture comprising 2 claim 16 ,3 claim 16 ,5-trimethylbenzoquinone is washed in a step (ii) with an ...

Novel quinochalcone compound and uses thereof for treating cancer or inflammation

Presented herein is a quinochalcone compound that displays strong anti-cancer properties and provides for synergistic anti-cancer activity when used in combination with interferon β (IFN-β) or interferon γ (IFN-γ). Accordingly, compositions comprising a quinochalcone compound, or a quinochalcone compound and an interferon are disclosed herein for use in treating cancer. Also presented herein, in some embodiments, are methods of using a quinochalcone compound, and compositions thereof, to treat inflammation.

Mixtures of matrix materials and organic semiconductors capable of emission, use of the same and electronic components containing said mixtures

The invention relates to novel mixtures consisting of at least two substances, one substance being used as a matrix material and the other as a material which is capable of emission and contains at least one element having an atomic number larger than 20. The invention also relates to the use of said mixtures in organic electronic components such as electroluminescence elements and displays.

Concerted processes for forming 1,2,4-trihydroxybenzene from hydroquinone

Flow batteries incorporating an active material with one or more catecholate ligands can have a number of desirable operating features. Commercial syntheses of catechol produce significant quantities of hydroquinone as a byproduct, which presently has limited value in the battery industry and can represent a significant waste disposal issue at industrial production scales. Using a concerted, high-yield process, low-value hydroquinone can be transformed into high-value 1,2,4-trihydroxybenzene, which can be a desirable ligand for active materials of relevance in the flow battery industry. Methods for forming 1,2,4-trihydroxybenzene can include: oxidizing hydroquinone in a first reaction to form p-benzoquinone, converting the p-benzoquinone in a second reaction to form 1,2,4-triacetoxybenzene, deacetylating the 1,2,4-triacetoxybenzene in a third reaction to form 1,2,4-trihydroxybenzene, and isolating the 1,2,4-trihydroxybenzene after performing the first reaction, the second reaction and the third reaction consecutively.

Mixtures of matrix materials and organic semiconductors capable of emission, use of the same and electronic components containing said mixtures

본 발명은 하나의 물질이 매트릭스 재료로서 이용되고, 다른 하나는 방출가 가능하고 원자 번호 20 초과인 하나 이상의 원소를 함유하는 물질로서 이용되는, 2 개 이상의 물질로 이루어진 신규 혼합물에 관한 것이다. 본 발명은 또한 전계발광 요소 및 디스플레이와 같은 유기 전자 부품에서의 상기 혼합물의 용도에 관한 것이다. The present invention relates to a novel mixture of two or more materials in which one material is used as the matrix material and the other is capable of being released and containing one or more elements having an atomic number greater than 20. The invention also relates to the use of said mixture in organic electronic components such as electroluminescent elements and displays.

Способ получения 2, 3, 5-триметилбензохинона при помощи окисления 2, 3, 6-триметилфенола

А 2016103145 ко РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) 1] хх < д < Хх < РИ "’ 23: (50) МПК С07С 46/08 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2016103145, 25.06.2014 (71) Заявитель(и): БАСФ СЕ (ОЕ) Приоритет(ы): (30) Конвенционный приоритет: (72) Автор(ы): 02.07.2013 ЕР 13174688.5; ДЭН Рихард (ОЕ), 02.07.2013 95$ 61/841,946 КЛАУС Михаель (ОЕ), (43) Дата публикации заявки: 07.08.2017 Бюл. № 22 я АНП. Е (85) Дата начала рассмотрения заявки РСТ на ТЕЛЕС Йоахим Энрике (РЕ) национальной фазе: 02.02.2016 (86) Заявка РСТ: ЕР 2014/063425 (25.06.2014) (87) Публикация заявки РСТ: УГО 2015/000767 (08.01.2015) Адрес для переписки: 105064, Москва, а/я 88, "Патентные поверенные Квашнин, Сапельников и партнеры" (54) СПОСОБ ПОЛУЧЕНИЯ 2, 3, 5-ГРИМЕТИЛБЕНЗОХИНОНА ПРИ ПОМОЩИ ОКИСЛЕНИЯ 2, 3, 6-ТРИМЕТИЛФЕНОЛА (57) Формула изобретения 1. Способ получения 2,3,5-триметилбензохинона или смеси, содержащей 2,3,5- триметилбензохинон, включающий в себя следующую стадию: (1) окисление 2,3,6-триметилфенола до 2,3,5-триметилбензохинона с помощью кислорода или кислородсодержащего газа в двух- или многофазной реакционной среде в присутствии катализатора или каталитической системы, содержащей по меньшей мере галогенид меди (ПП), так что образуется смесь, содержащая 2,3,5- триметилбензохинон, отличающийся тем, что реакционная среда содержит воду и по меньшей мере один вторичный алифатический ациклический спирт, имеющий 6 или более, предпочтительно 7 или более, атомов углерода. 2. Способ по п. 1, отличающийся тем, что катализатор или каталитическая система содержит хлорид меди (П). 3. Способ по п. 1 или 2, отличающийся тем, что катализатор или каталитическая система, кроме того, содержит по меньшей мере один галогенид щелочного металла, предпочтительно хлорид лития. 4. Способ по п. 1 или 2, отличающийся тем, что реакционная среда содержит 3- гептанол. 5. Способ по п. 1 или 2, отличающийся тем, что этот способ проводится в Стр.: 1 па ЗУ ГОС У А ...

从氢醌形成1,2,4-三羟基苯的协同方法

本发明公开了包含具有一个或多个儿茶酚配体的活性材料的液流电池可具有许多期望的工作特征。儿茶酚的商业合成产生大量的氢醌作为副产物，所述副产物目前在电池工业中的价值有限并且可造成工业生产规模上的重大废物处理问题。使用协同的高收率工艺，可以将低价值的氢醌转变为高价值的1,2,4‑三羟基苯，所述1,2,4‑三羟基苯可以是液流电池工业中相关的活性材料的理想配体。形成1,2,4‑三羟基苯的方法可包括：在第一反应中氧化氢醌以形成对苯醌，在第二反应中转化对苯醌以形成1,2,4‑三乙酰氧基苯，在第三反应中将1,2,4‑三乙酰氧基苯脱乙酰化以形成1,2,4‑三羟基苯，以及在接连进行第一反应、第二反应和第三反应后分离1,2,4‑三羟基苯。

Phenyl bisphenol derivative, preparation method and medical application thereof

本发明涉及苯双酚衍生物及其制备方法和在医药上的应用。本发明的苯双酚衍生物能够促进镇静催眠、脑保护，治疗和/或预防中枢神经系统相关的疾病。

Mixture of matrix material and organic semiconductor capable of emitting light, use thereof, and electronic component comprising said mixture

A mixture contains a matrix material containing specified units; and a material which is capable of emission and which contains an element of atomic number above 20. A mixture contains (a) a matrix material containing units of formula C:Q where Q = a non-bonding electron pair comprising O, S, Se or N; and (b) a material which is capable of emission and which contains an element of atomic number above 20. An independent claim is also included for novel aromatic or heteroaromatic compounds of formulae (10a)-(15). [Image] Z : CR1> or N; Y : N; R1> - R3> which must be different from each other : (a) H, CN, optionally cyclic 1-40C alkyl, alkoxy or alkylamino optionally with one or more non-adjacent -CH2- groups replaced by -R4>C=CR4>-, -Ctriple boundC-, C=O, C=S, C=Se, C=NR4>, -O-, -S-, -NR5>- or -CONR6>- and optionally with one or more H replaced by F, Cl, Br or I or (b) a 1-40C (hetero)aromatic system optionally with one or more H replaced by F, Cl, Br or I and optionally substituted by one or more non- aromatic residue R1> where one or more R1> and/or R1>, R2> are on the same or different rings or stretch between a mono and poly-cyclic aliphatic or aromatic ring system; and R4> - R6>H or 1-20C aliphatic or aromatic hydrocarbon; Ar : a 2- 40C (hetero)aromatic system optionally with one or more H replaced by F, Cl, Br or I and optionally substituted with one or more non-aromatic residue R1> as per (b) above; n : 0 or 1; E : C or N; R7>(a) 1-40C alkyl, alkoxy or alkylamino optionally with one or more non-adjacent -CH2- groups replaced by -R4>C=CR4>-, -C=C-, C=O, C=S, C=Se, C=NR4>, -O-, -S-, -NR4>- or -CONR4>-; (b) an aromatic group optionally substituted by halogen, alkyl, -CF3, -OH, -SH, -S-alkyl, alkoxy, - NO2, -CN, -COOH, -COOAlkyl, -NH2, -Nalkyl, benzyl or benzoyl; or (c) a 2-40C large aromatic system optionally with one or more H replaced by F, Cl, Br or I and optionally substituted by one or more non- ...

SALT MELT, METHOD FOR ITS PRODUCTION AND METHOD FOR PRODUCING HYDROGEN PEROXIDE

ÐÎÑÑÈÉÑÊÀß ÔÅÄÅÐÀÖÈß (19) RU (11) 2006 145 504 (13) A (51) ÌÏÊ C07C 50/02 (2006.01) ÔÅÄÅÐÀËÜÍÀß ÑËÓÆÁÀ ÏÎ ÈÍÒÅËËÅÊÒÓÀËÜÍÎÉ ÑÎÁÑÒÂÅÍÍÎÑÒÈ, ÏÀÒÅÍÒÀÌ È ÒÎÂÀÐÍÛÌ ÇÍÀÊÀÌ (12) ÇÀßÂÊÀ ÍÀ ÈÇÎÁÐÅÒÅÍÈÅ (21), (22) Çà âêà: 2006145504/04, 30.06.2005 (71) Çà âèòåëü(è): ÄÇÅ ÊÓÈÍÇ ÞÍÈÂÅÐÑÈÒÈ ÎÔ ÁÅËÔÀÑÒ (GB) (30) Êîíâåíöèîííûé ïðèîðèòåò: 30.06.2004 GB 0414597.5 (72) Àâòîð(û): ÄÎÝÐÒÈ Ýíäðþ Ï. (GB) (43) Äàòà ïóáëèêàöèè çà âêè: 20.08.2008 Áþë. ¹ 23 (87) Ïóáëèêàöè PCT: WO 2006/003395 (12.01.2006) Àäðåñ äë ïåðåïèñêè: 191186, Ñàíêò-Ïåòåðáóðã, à/ 230, "ÀÐÑÏÀÒÅÍÒ", ïàò. ïîâ. Â.Â.Äîùå÷êèíîé (54) ÑÎËÅÂÎÉ ÐÀÑÏËÀÂ, ÑÏÎÑÎÁ ÅÃÎ ÏÎËÓ×ÅÍÈß È ÑÏÎÑÎÁ ÏÎËÓ×ÅÍÈß ÏÅÐÅÊÈÑÈ A ÂÎÄÎÐÎÄÀ 2 0 0 6 1 4 5 5 0 4 R U - Ñòðàíèöà: 1 RU A (57) Ôîðìóëà èçîáðåòåíè 1. Ñîëåâîé ðàñïëàâ (Cat An ), ñîäåðæàùèé õèíîí èëè ïðîèçâîäíîå õèíîíà êàê àíèîí èëè êàòèîí, ïðè÷åì óêàçàííûé õèíîí èëè ïðîèçâîäíîå õèíîíà èìååò ñòðóêòóðó ôîðìóëû I, II èëè III + 2 0 0 6 1 4 5 5 0 4 (86) Çà âêà PCT: GB 2005/002565 (30.06.2005) R U (85) Äàòà ïåðåâîäà çà âêè PCT íà íàöèîíàëüíóþ ôàçó: 30.01.2007 A 2 0 0 6 1 4 5 5 0 4 R U A Ñòðàíèöà: 2 2 0 0 6 1 4 5 5 0 4 3. Ñîëåâîé ðàñïëàâ ïî ëþáîìó èç ïï.1 èëè 2, ãäå êàòèîí âûáðàí èç ãðóïïû, ñîñòî ùåé èç èìèäàçîëè , ïèïåðèäèíè , ôîñôîíè è ÷åòâåðòè÷íûõ àìèíîãðóïï. 4. Ñîëåâîé ðàñïëàâ ïî ï.1, ñîäåðæàùèé õèíîí èëè ïðîèçâîäíîå õèíîíà â âèäå êàòèîíà, ãäå À âûáðàí èç ãðóïïû, ñîñòî ùåé èç èìèäàçîëè , ïèïåðèäèíè , ïèðèäèíè , ôîñôîíè , èîíîâ ïèðàçèíè , ÷åòâåðòè÷íûõ àìèíîâ è èõ ïðîèçâîäíûõ. 5. Ñîëåâîé ðàñïëàâ ïî ï.1, ñîäåðæàùèé õèíîí èëè ïðîèçâîäíîå õèíîíà â âèäå êàòèîíà, ãäå îäèí èëè áîëåå ÷åì îäèí àòîì êîëüöà ïðåäñòàâë åò ñîáîé êâàòåðíèçîâàííûé ãåòåðîàòîì, è êàæäûé êâàòåðíèçîâàííûé ãåòåðîàòîì íåçàâèñèìî ïðåäñòàâë åò ñîáîé ãðóïïó èìèäàçîëè , ïèïåðèäèíè , ïèðèäèíè , ôîñôîíè , ïèðàçèíè , ÷åòâåðòè÷íîãî àìèíà, àììîíè èëè èõ ïðîèçâîäíîå, è À ïðåäñòàâë åò âîäîðîä, C1-10àëêèëüíóþ ãðóïïó ñ íåðàçâåòâëåííîé, ðàçâåòâëåííîé öåïüþ èëè öèêëè÷åñêóþ, àðèëüíóþ ãðóïïó, ãåòåðîöèêëè÷åñêóþ ãðóïïó, CN, ÎÍ èëè NO2, ãäå óêàçàííûå àëêèëüíûå è ...

Method for producing 2,3,5-trimethyl benzoquinone by oxidation of 2,3,6-trimethylphenol

FIELD: chemistry; technological processes. SUBSTANCE: present invention relates to a method for producing 2,3,5-trimethyl benzoquinone or a mixture containing 2,3,5-trimethyl benzoquinone, which are used to produce vitamin E. Method comprises the step of oxidation of 2,3,6-trimethylphenol to 2,3,5-trimethyl benzoquinone with oxygen or an oxygen-containing gas in a two- or multi-phase reaction medium in the presence of a catalyst or catalyst system containing at least a copper (ll) halide, so that a mixture containing 2,3,5-trimethyl benzoquinone is formed. Reaction medium contains water and at least one secondary aliphatic acyclic alcohol having 6 or more carbon atoms. Invention also relates to a mixture for the synthesis of vitamin E containing 2,3,5-trimethyl benzoquinone, to use of a secondary aliphatic acyclic alcohol having 6 or more carbon atoms and to use of the mixture produced by the proposed method. EFFECT: proposed method allows maximally preventing the formation of chlorinated byproducts, thereby improving the selectivity of the process. 18 cl, 1 tbl, 12 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 668 962 C2 (51) МПК C07C 46/08 (2006.01) C07C 50/02 (2006.01) C07C 31/125 (2006.01) C07D 311/72 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК C07C 46/08 (2006.01); C07D 311/72 (2006.01) (21)(22) Заявка: 2016103145, 25.06.2014 (24) Дата начала отсчета срока действия патента: Дата регистрации: 05.10.2018 02.07.2013 EP 13174688.5; 02.07.2013 US 61/841,946 (56) Список документов, цитированных в отчете о поиске: EP 0369823 А1, 23.05.1990. EP (43) Дата публикации заявки: 07.08.2017 Бюл. № 22 0475272 B1, 11.01.1995. RU 2163600 C2, 27.02.2001. RU 2165406 C1, 20.04.2001. (45) Опубликовано: 05.10.2018 Бюл. № 28 C 2 C 2 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 02.02.2016 (86) Заявка PCT: EP 2014/063425 (25.06.2014) 2 6 6 8 9 6 2 (87) Публикация заявки PCT: R U 2 6 6 8 9 6 2 (73) ...

Mixtures of matrix materials and organic semiconductors capable of emission, use of the same and electronic components containing said mixtures

The present invention describes new types of material mixtures composed of at least two substances, one serving as a matrix material and the other being an emission material capable of emission, the latter comprising at least one element of atomic number greater than 20, and the use thereof in organic electronic components such as electroluminescent elements and displays.

Mixture of organic emission-enabled semiconductors and matrix materials, use of same and electronic components containing same

A mixture contains a matrix material containing specified units; and a material which is capable of emission and which contains an element of atomic number above 20. A mixture contains (a) a matrix material containing units of formula C:Q where Q = a non-bonding electron pair comprising O, S, Se or N; and (b) a material which is capable of emission and which contains an element of atomic number above 20. An independent claim is also included for novel aromatic or heteroaromatic compounds of formulae (10a)-(15). [Image] Z : CR 1> or N; Y : N; R 1> - R 3> which must be different from each other : (a) H, CN, optionally cyclic 1-40C alkyl, alkoxy or alkylamino optionally with one or more non-adjacent -CH 2- groups replaced by -R 4>C=CR 4>-, -Ctriple boundC-, C=O, C=S, C=Se, C=NR 4>, -O-, -S-, -NR 5>- or -CONR 6>- and optionally with one or more H replaced by F, Cl, Br or I or (b) a 1-40C (hetero)aromatic system optionally with one or more H replaced by F, Cl, Br or I and optionally substituted by one or more non- aromatic residue R 1> where one or more R 1> and/or R 1>, R 2> are on the same or different rings or stretch between a mono and poly-cyclic aliphatic or aromatic ring system; and R 4> - R 6>H or 1-20C aliphatic or aromatic hydrocarbon; Ar : a 2- 40C (hetero)aromatic system optionally with one or more H replaced by F, Cl, Br or I and optionally substituted with one or more non-aromatic residue R 1> as per (b) above; n : 0 or 1; E : C or N; R 7>(a) 1-40C alkyl, alkoxy or alkylamino optionally with one or more non-adjacent -CH 2- groups replaced by -R 4>C=CR 4>-, -C=C-, C=O, C=S, C=Se, C=NR 4>, -O-, -S-, -NR 4>- or -CONR 4>-; (b) an aromatic group optionally substituted by halogen, alkyl, -CF 3, -OH, -SH, -S-alkyl, alkoxy, - NO 2, -CN, -COOH, -COOAlkyl, -NH 2, -Nalkyl, benzyl or benzoyl; or (c) a 2-40C large aromatic system optionally with one or more H replaced by F, Cl, Br or I and optionally ...

Mixtures of matrix materials and organic semiconductors capable of emission, use of the same and electronic components containing said mixtures

Mischungen von organischen zur Emission befähigten Halbleitern und Matrixmaterialien, deren Verwendung und Elektronikbauteile enthaltend diese Mixtures of organic emission-capable semiconductors and matrix materials, their use and electronic components containing them Die vorliegende Erfindung beschreibt neuartige Materialmischungen aus mindestens zwei Substanzen, wobei die eine als Matrixmaterial dient und die andere ein zur Emission befähigtes Emissionsmaterial ist, welches mindestens ein Element der Ordungszahl größer 20 enthält, und deren Verwendung in organischen elektronischen Bauteilen wie Elektrolumineszenzelementen und Displays. The present invention describes novel mixtures of materials comprising at least two substances, one serving as a matrix material and the other being an emission material capable of emitting at least one element of the order number greater than 20, and their use in organic electronic components such as electroluminescent elements and displays.

Mixtures of matrix materials and organic semiconductors capable of emission, use of the same and electronic components containing said mixtures

Die vorliegende Erfindung beschreibt neuartige Materialmischungen aus mindestens zwei Substanzen, wobei die eine als Matrixmaterial dient und die andere ein zur Emission befähigtes Emissionsmaterial ist, welches mindestens ein Element der Ordungszahl grösser 20 enthält, und deren Verwendung in organischen elektronischen Bauteilen wie Elektrolumineszenzelementen und Displays.

Mixture of organic emission-enabled semiconductors and matrix materials, use of same and electronic components containing same

Die vorliegende Erfindung beschreibt neuartige Materialmischungen aus mindestens zwei Substanzen, wobei die eine als Matrixmaterial dient und die andere ein zur Emission befähigtes Emissionsmaterial ist, welches mindestens ein Element der Ordungszahl größer 20 enthält, und deren Verwendung in organischen elektronischen Bauteilen wie Elektrolumineszenzelementen und Displays. The present invention describes novel material mixtures of at least two substances, one serving as a matrix material and the other being an emission material capable of emitting which contains at least one element of order number greater than 20 and their use in organic electronic components such as electroluminescent elements and displays.

Mixtures of organic semiconductors capable of emission and matrix materials, their use and electronic components containing them

Mischungen enthaltend- mindestens ein Matrixmaterial A gemäß Formel (1), Formel (2), Formel (3), Formel (10) oder Formel (11), welches A eine Glastemperatur Tg(gemessen als Reinsubstanz) größer 70 °C aufweist,wobei die Symbole und Indizes folgende Bedeutung haben:X ist O;Y ist N;Z ist gleich oder verschieden bei jedem Auftreten CR1oder N,R1, R2, R3ist gleich oder verschieden bei jedem Auftreten eine geradkettige oder verzweigte oder cyclische Alkyl- oder Alkoxygruppe mit 1 bis 40 C-Atomen, wobei ein oder mehrere nicht benachbarte CH2-Gruppen durch -O-, -S-, -NR5- oder -CONR6- ersetzt sein können und wobei ein oder mehrere H-Atome durch F ersetzt sein können, oder eine Aryl- oder Heteroarylgruppe mit 1 bis 40 C-Atomen, wobei ein oder mehrere H-Atome durch F, Cl, Br, I ersetzt sein können und die durch einen oder mehrere, nicht aromatische Reste R1substituiert sein kann;R5, R6sind gleich oder verschieden bei jedem Auftreten, H oder ein aliphatischer oder aromatischer Kohlenwasserstoffrest mit 1 bis 20 C-Atomen; und- mindestens ein zur Emission befähigtes Emissionsmaterial B, welches eine Verbindung ist, die bei geeigneter Anregung Licht emittiert und mindestens ein Atom aus der Gruppe Iridium oder Platin enthält. Mixtures containing at least one matrix material A according to formula (1), formula (2), formula (3), formula (10) or formula (11), which A has a glass transition temperature Tg (measured as pure substance) greater than 70 ° C, wherein the symbols and indices have the following meanings: X is O; Y is N; Z is identically or differently on each occurrence CR1 or N, R1, R2, R3 is identically or differently on each occurrence a straight-chain or branched or cyclic alkyl or alkoxy group with 1 up to 40 carbon atoms, where one or more non-adjacent CH2 groups can be replaced by -O-, -S-, -NR5- or -CONR6- and where one or more H atoms can be replaced by F, or one Aryl or heteroaryl group with 1 to 40 carbon atoms, where one or more H atoms can be replaced by F, Cl, ...

Quinone compound and its preparation

Mixtures of matrix materials and organic semiconductors capable of emission, use of the same and electronic components containing said mixtures

本发明公开了基质材料和能够发光的有机半导体的混合物、其用途和含有所述混合物的电子元件。具体地，本发明公开由至少两种物质组成的新型材料混合物，一种物质用作基质材料，另一种物质是能够发光的发光材料，发光材料包括至少一种原子数大于20的元素，也公开了该混合物在有机电子元件如电致发光元件和显示器中的用途。

Process for the preparation of coenzyme Qn and intermediates thereof

본 발명은 건강보조식품이나 의약의 활성물질로 광범위하게 사용되는 하기 화학식 1의 코엔자임 Q n (n=1-12)의 제조방법 및 코엔자임 Q n 의 제조과정에서 생성되는 신규한 중간체에 관한 것이다. The present invention relates to a process for the preparation of coenzyme Q n (n = 1-12) of the general formula (1), which is widely used as an active ingredient in dietary supplements or medicaments, and to novel intermediates produced during the preparation of coenzyme Q n . 상기 식에서, R 2 , R 3 및 n은 명세서에 정의한 바와 같다. Wherein R 2 , R 3 and n are as defined in the specification. 코엔자임 Qn, 비타민 K, 폴리프레닐트리메틸 퀴논, 하이드로퀴논 유도체, 염화철 Coenzyme Qn, Vitamin K, Polyprenyltrimethyl Quinone, Hydroquinone Derivative, Iron Chloride

Preparation method of quinone compound

本发明公开了一种醌类化合物的制备方法。本发明提供了一种醌类化合物的制备方法，其包括下述步骤：在碱的存在下，将如式II所示的化合物和如式III所示的化合物进行缩合反应，得到如式I所示的醌类化合物即可；所述的碱的碱性强于苯酚钠。该方法操作简单，适于工业化生产。

Compound for treating lipase-mediated diseases

FIELD: chemistry. ^ SUBSTANCE: invention relates to novel compounds - benzoquinone derivatives of formula (I): , where each of R1 and R2 is O-C(O)phenyl; where the phenyl is substituted with 1 substitute selected from halide, nitro, C1-C6 alkyl or C1-C6 alkoxy, and pharmaceutically acceptable salts thereof. ^ EFFECT: low activity of pancreatic lipase based on compounds of the said formula. ^ 6 cl, 3 tbl, 23 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (51) МПК C07C C07C A61K A61K A61P A61P ФЕДЕРАЛЬНАЯ СЛУЖБА A61P ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, A61P ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ A61P A61P (12) ОПИСАНИЕ 2 420 513 69/76 (2006.01) 205/57 (2006.01) 8/37 (2006.01) 31/216 (2006.01) 1/18 (2006.01) 3/04 (2006.01) 3/06 (2006.01) 3/10 (2006.01) 9/10 (2006.01) 31/04 (2006.01) A61P A61Q A61Q A61Q A61K A61K A61K (13) C2 43/00 5/00 19/06 90/00 8/30 31/21 31/235 (2006.01) (2006.01) (2006.01) (2009.01) (2006.01) (2006.01) (2006.01) ИЗОБРЕТЕНИЯ К ПАТЕНТУ (21)(22) Заявка: 2008106628/04, 19.09.2005 (24) Дата начала отсчета срока действия патента: 19.09.2005 (73) Патентообладатель(и): РЕЛАЙАНС ЛАЙФ САЙЕНСИЗ ПВТ ЛТД (IN) (43) Дата публикации заявки: 27.08.2009 Бюл. № 24 C 2 2 4 2 0 5 1 3 R U (85) Дата начала рассмотрения заявки PCT на национальной фазе: 21.02.2008 (86) Заявка PCT: IN 2005/000318 (19.09.2005) (87) Публикация заявки РСТ: WO 2007/010546 (25.01.2007) Адрес для переписки: 129090, Москва, ул. Б.Спасская, 25, стр.3, ООО "Юридическая фирма Городисский и Партнеры", пат.пов. Е.Е.Назиной (54) СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ ЛИПАЗОЙ (57) Реферат: Изобретение относится соединениям - производным формулы (I): к новым бензохинонов Ñòð.: 1 ru C 2 (56) Список документов, цитированных в отчете о поиске: DATABASE BEILSTEIN Beilstein Institut zur Förderung der Chemischen Wissenschaft, Frankfurt am Main, DE; XP002376638 retrieved from XFIRE Database accession no. 3533410, 3512474, 3533032, 3522157, 3517643 & CHEM. ZENTRALBL., vol.101, no.1, 1930, page 395. DATABASE BEILSTEIN ...

Quinone derivatives which exhibit antioxidant activity

본 발명은 항산화 활성을 가지는 다음 화학식 1로 표시되는 퀴논 화합물과 그의 약제학적으로 허용가능한 염에 관한 것이다. The present invention relates to a quinone compound represented by the following formula (1) having an antioxidant activity and a pharmaceutically acceptable salt thereof. 상기 화학식 1에서 : R 1 , R 2 , R 3 , X 및 n은 각각 발명의 상세한 설명에서 정의한 바와 같다. In Formula 1: R 1 , R 2 , R 3 , X and n are as defined in the detailed description of the invention, respectively.

Method for the preparation of 2,3,5-trimethylbenzoquinone

본 발명은 2,3,5-트리메틸벤조퀴논의 제조방법에 관한 것으로, 좀 더 상세하게는 용매 및 산화제 존재하에서 2,3,5-트리메틸페놀 또는 2,3,6-트리메틸페놀을 산화촉매로 붕소화합물을 사용하여 반응시켜 2,3,5-트리메틸벤조퀴논을 제조하는 방법에 관한 것이다. 본 발명에 사용된 산화제와 촉매는 상업적으로 손쉽게 구입할 수 있는 화합물인바, 본 발명을 통해서 2,3,5-트리메틸벤조퀴논을 경제적으로 대량생산이 가능하게 하는 효과가 있다. The present invention relates to a method for preparing 2,3,5-trimethylbenzoquinone, and more particularly, to 2,3,5-trimethylphenol or 2,3,6-trimethylphenol in the presence of a solvent and an oxidizing agent. It relates to a method for producing 2,3,5-trimethylbenzoquinone by reacting with a boron compound. The oxidizing agent and catalyst used in the present invention are commercially available compounds, and thus, the present invention has the effect of enabling economically mass production of 2,3,5-trimethylbenzoquinone.

Tetra-substituted diphenoquinone

Patent JPH0451536B2

Preparation of 2,6- and 2,7-disubstituted anthraquinone derivatives

본 발명은, 바람직하게는 과산화수소의 제조에 사용될 수 있는, 신규한 안트라퀴논 유도체, 2,6-디이소헥실안트라센-9,10-디온 및 2,7-디이소헥실-안트라센-9,10-디온, 및 이들 안트라퀴논 유도체의 제조 방법에 관한 것이다. The present invention relates to novel anthraquinone derivatives, 2,6-diisohexylanthracene-9,10-dione and 2,7-diisohexyl-anthracene-9,10-, which can preferably be used for the production of hydrogen peroxide Diones and methods for preparing these anthraquinone derivatives.

Method for producing 2,3,5-trimethylbenzoquinone by oxidation of 2,3,6-trimethylphenol

Extruded product

Bis-aminomethyl-anthraquinone derivative

Oxidative coupling of phenols and naphthols

Abstract of the Disclosure Self-condensation products obtained by the coupling of alkylphenols, alkoxyphenols or naphthols are prepared by contacting an aqueous mixture of the phenol or naphthol with oxygen or an oxygen-containing gas in the presence of a catalyst system comprising (a) a copper compound, (b) an anionic surfactant, and (c) an alkaline material.

Oxidation process of phenols

OXIDIZING CONDENSATION OF ALKYLPHENOLS CATALYZED BY METAL COMPLEXES OF AMINE COMPOUNDS

Improvements in processes for the formation of autocondensation products of phenols

Process for oxidizing a phenol to a p-benzoquinone

ABSTRACT Phenol or a substituted phenol is oxidized to the corresponding benzoquinone or substituted benzoquinone in a nitroalkane solvent in the presence of a copper ion catalyst promoted with a base selected from alkali metal phenoxides, and secondary or tertiary lower alkyl amines.

Para-benzoquinone prepn. by alkylphenol oidn. - in the presence of a cobalt di(salicylal)diimino-dipropylamine complex

The prepn. of p-benzoquinones (I) is carried out by oxidising an alkylphenol (II) with O2 or an O2-contg. gas in an org. solvent in the presence of a cobalt 3,3'-di(salicylal)-diimino-dipropylamine deriv. (III) and an amine (pref. with a pKa of 9-11). The reaction is pref. effected at 10-50 degrees C with an O2 partial pressure of =5 bar using 0.001-0.1 mole (III) per mole of (II) and 1 mole of amine per mole of (III). The alkylphenol (II) is pref. 2,3,5-trimethylphenol or 2,5-dimethylphenol. (III) is esp. Co 3,3'-di(salicylal)-diimino-dipropylamine or -dipropylmethylamine.

Electrophotographic photoreceptor

Oxidation process of phenols and polyphenols

PROCESS FOR PREPARATION OF AUTOCONDENSATION PRODUCTS

Patent FR1591651A

PEARLS OF A PHENOLIC COMPOUND AND THEIR PROCESS FOR OBTAINING

La présente invention a pour objet une nouvelle présentation d'un composé phénolique sous forme solide. L'invention vise plus particulièrement les perles d'hydroquinone. L'invention se rapporte aussi à la préparation desdites perles.La caractéristique du procédé de l'invention est de préparer à chaud, une solution aqueuse concentrée d'un composé phénolique, puis de fragmenter la solution en gouttelettes et de refroidir les gouttelettes obtenues dans un courant gazeux de telle sorte qu'elles se solidifient en perles qui sont ensuite récupérées puis séchées. The subject of the present invention is a new presentation of a phenolic compound in solid form. The invention relates more particularly to hydroquinone beads. The invention also relates to the preparation of said pearls. The characteristic of the process of the invention is to prepare hot, a concentrated aqueous solution of a phenolic compound, then to fragment the solution into droplets and to cool the droplets obtained in a gas stream so that they solidify into beads which are then collected and dried.

Concerted processes for forming 1,2,4-trihydroxybenzene from hydroquinone

Flow batteries incorporating an active material with one or more catecholate ligands can have a number of desirable operating features. Commercial syntheses of catechol produce significant quantities of hydroquinone as a byproduct, which presently has limited value in the battery industry and can represent a significant waste disposal issue at industrial production scales. Using a concerted, high-yield process, low-value hydroquinone can be transformed into high-value 1,2,4-trihydroxybenzene, which can be a desirable ligand for active materials of relevance in the flow battery industry. Methods for forming 1,2,4-trihydroxybenzene can include: oxidizing hydroquinone in a first reaction to form p-benzoquinone, converting the p-benzoquinone in a second reaction to form 1,2,4-triacetoxybenzene, deacetylating the 1,2,4-triacetoxybenzene in a third reaction to form 1,2,4-trihydroxybenzene, and isolating the 1,2,4-trihydroxybenzene after performing the first reaction, the second reaction and the third reaction consecutively.

Method for producing isoprenoid quinones

METHOD OF PRODUCING ISOPRENOID QUINONE COMPOUNDS OF THE FORMULA (2-CH3,5-R2,6-R1-1,4-BENZOQUINON-3-YL)-CH2-CH=C(-CH3)-CH2- (CH2-CH(-P)-C(-CH3)(-Q)-CH2)N-H USEFUL AS VITAMINS OR COENZYMES, WHERE R1 AND R2 ARE METHOXY OR METHYL OR TAKEN TOGETHER REPRESENT -CH=CH-CH=CH- P AND Q ARE HYDROGEN ATOMS OR TAKEN TOGETHER A DOUBLE BOND AND N IS AN INTEGER OF FROM 0 TO 9, BY SUBJECTING ONE OF THE COMPOUNDS OF THE FORMULAE -CH=CH-CH=CH- WHERE R1 AND R2 ARE AS ABOVE-DEFINED, TO CONDENSATION WITH A COMPOUND OF THE FORMULA 2-R2,3-R1,5-R3-1,4-BENZOQUINONE AND 2-R2,3-R1,5-CH3-HYDROQUINONE WHERE P,Q AND N ARE AS ABOVE-DEFINED AND X IS HALOGEN, IN THE PRESENCE OF ZINC AMALGAM OR PALLADIUM AND SUBJECTING THE CONDENSATION PRODUCT TO OXIDATION.

4-hydroxytetrahydropyran-2-one derivatives

4-hydroxytetrahydropyran-2-one derivatives with general formula (I) are useful as cholesterol reducing agents as well as lipid reducing agents, serving as inhibitors of HMG-CoA reductase, and capable of inhibiting the biosynthesis of peroxidized lipids, and therefore effective for curing arteriosclerosis: ##STR1## wherein R 1 represent hydrogen or a 2-tetrahydropyranyl group; R 2 and R 3 each represent hydrogen or an alkyl group having 1 to 6 carbon atoms; R 4 represents hydrogen, an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, an aryl group, an aralkyl group, an acyl group, an aroyl group or a substituted sulfonyl group; A represents --CH 2 CH 2 --, or --CH═CH--; and n is an integer of 1 or 2, and intermediates for synthesizing the 4-hydroxytetrahydropyran-2-one derivatives are disclosed.

Oxidative coupling of alkylphenols, alkoxyphenols and naphthols catalyzed by metal complexes of amino carboxylic and amino sulfonic acids

Self-condensation products obtained by the oxidative coupling of certain alkylphenols, alkoxyphenols or naphthols are prepared by contacting an aqueous mixture of the phenol or naphthol with oxygen in the presence of a metal complex of an aminocarboxylic acid or an aminosulfonic acid.

Method for preparing bis-aminomethyl-anthraquinone derivatives

내용 없음

Novel cannabigerol derivatives

The present invention relates to novel cannabigerol quinone derivatives of formula (I) wherein R is the carbon atom of a linear or branched group, represented by: aryl, alkenyl, alkynyl or alcoxycarbonil groups; or wherein R is the nitrogen atom of a linear or branched group, represented by: alkylamino, arylamino, alkenylamino or alkynylamino groups; or, alternatively, R represents a bond between 2 molecules of formula (I) forming a dimer. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating PPARg-related diseases due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.

QUINONES BY THALLIC OXIDATION OF PHENOLS

Patent FR2020840A1

Concerted processes for forming 1,2,4-trihydroxybenzene from hydroquinone

Flow batteries incorporating an active material with one or more catecholate ligands can have a number of desirable operating features. Commercial syntheses of catechol produce significant quantities of hydroquinone as a byproduct, which presently has limited value in the battery industry and can represent a significant waste disposal issue at industrial production scales. Using a concerted, high-yield process, low-value hydroquinone can be transformed into high-value 1,2,4-trihydroxybenzene, which can be a desirable ligand for active materials of relevance in the flow battery industry. Methods for forming 1,2,4-trihydroxybenzene can include: oxidizing hydroquinone in a first reaction to form p-benzoquinone, converting the p-benzoquinone in a second reaction to form 1,2,4-triacetoxybenzene, deacetylating the 1,2,4-triacetoxybenzene in a third reaction to form 1,2,4-trihydroxybenzene, and isolating the 1,2,4-trihydroxybenzene after performing the first reaction, the second reaction and the third reaction consecutively.

Method for producing 2,3,5-trimethyl benzoquinone by oxidation of 2,3,6-trimethylphenol

本发明涉及制备2,3,5-三甲基苯醌或包含2,3,5-三甲基苯醌的化合物的方法，所述方法包括以下步骤：将2,3,6-三甲基苯酚在两相或多相反应介质中在包含至少一种铜(II)卤化物的催化剂或催化剂体系的存在下用氧气或含氧气体氧化成包含2,3,5-三甲基苯醌的混合物，其特征在于反应介质包含水和至少一种具有6个或更多，优选7个或更多碳原子的仲脂族无环醇。

Adducts of keto compounds and anions of oxa acids, processes for their preparation, their use and azoketo compounds.

Process for the manufacture of quinones

Patent JPWO2021132640A1

Novel cannabigerol derivatives

본 발명은 화학식 (I)로 표시되는 신규 카나비제롤 퀴논 유도체에 관한 것이다: 화학식 (I) [여기서, R은 선형 또는 분지형 기의 탄소 원자로써, 아릴, 알케닐, 알키닐 또는 알콕시카르보닐 기로 표현되는 것이거나; 또는 R은 선형 또는 분지형 기의 질소 원자로써, 알킬아미노, 아릴아미노, 알케닐아미노 또는 알키닐아미노 기로 표현되는 것이거나; 또는 대안적으로 R은 이량체를 형성하는 화학식 (I)의 두 분자 사이의 결합을 나타낸다]. 또한, 본 발명은 치료 약제로써 사용되는, 특히 친전자체 활성(Nrf2 활성화) 및 세포독성 활성이 없이 높은 PPARg 작용제 효과로 인하여 PPARg 관련 질환을 치료하는데 사용되는, 화학식 (I)로 표시되는 임의의 화합물의 용도에 관한 것이다. 또한, 본 발명은 상기 화합물을 함유하는 약학 조성물 및 이 화합물로 질환을 치료하는 방법도 제공한다. The present invention relates to a novel cannabiderol quinone derivative represented by the formula (I): Formula (I) [wherein R is a carbon atom of a linear or branched group, which is represented by an aryl, alkenyl, alkynyl or alkoxycarbonyl group; or R is a nitrogen atom of a linear or branched group, which is represented by an alkylamino, arylamino, alkenylamino or alkynylamino group; or alternatively R represents a bond between two molecules of formula (I) forming a dimer]. The present invention also relates to any compound represented by formula (I) for use as a therapeutic agent, in particular for treating PPARg related diseases due to its high PPARg agonist effect without electrophilic activity (Nrf2 activation) and cytotoxic activity is about the use of The present invention also provides pharmaceutical compositions containing said compounds and methods of treating diseases with said compounds.

Substituted dimethyl-benzoquinones and dimethyl-benzohydroquinones and a process forthe manufacture thereof

The invention comprises dimethylbenzo-(1 : 4)-quinones and -hydroquinones substituted by one or two radicals of formula <FORM:0880935/IV (b)/1> wherein n is 0-9 or the corresponding radical in which the double bond within the brackets is replaced by a single bond and also the 1-carboxylic acid acyl derivatives of the substituted hydroquinones. They are prepared by condensing a 2 : 3-, 2 : 5- or 2 : 6-dimethyl-benzo-1 : 4-hydroquinone or a 1-acyl derivative thereof in the presence of an acidio condensing agent, with a compound of formula <FORM:0880935/IV (b)/2> wherein X is a halogen atom or a hydroxy, acyloxy or alkoxy radical containing not more than eight carbon atoms and n is 0-9, or the corresponding compounds wherein the double bonds within the brackets are replaced by single bonds, and, if desired, hydrolysing the condensation product to remove the 1-acyl radical if present and/or oxidising the product to the corresponding benzoquinone derivative. In Examples: (1) 2 : 3-, 2 : 5- or 2 :6-dimethylbenzo-1 : 4-hydroquinone is reacted with isophytol in ether solution in the presence of zinc chloride and acetic acid, the product being separated chromatographically to give 2 : 3-, 2 : 5- or 2 : 6-dimethyl-3-mono- and -3 : 5-di-phytyl-benzo-1 : 4-quinones; (2) 2 : 3-dimethyl-benzo- 1 : 4-hydroquinone is reacted with isophytol in dioxan solution in the presence of zinc chloride to give 2 : 3-dimethyl-5-phytyl-benzo-1 : 4-hydroquinone which is oxidised with silver oxide in ether solution to the corresponding quinone; (3) 2 : 3-dimethyl-benzo-1 : 4-hydro-quinone is reacted with 3 : 7 : 11 : 15 : 19 : 23 : 27 : 31 : 35-nonamethylhexatriacontanonaen-(2 : 6 : 10 : 14: 8: 22 : 26 : 30 : 34)-ol-(1) as in (1) the product is oxidised as in (2) to the quinone which is purified chromatographically to give 2 : 3-dimethyl-5-[31 : 71 : 111 : 151 : 191 : 231 : 271 : 311 : 351-nonamethyl-hexatriacontanonaen-(21 : 61 : 101 : 141 : 181 : 221 : 261 : 301 : 341)-yl-(11)]- ...

Polymerization inhibitor for aromatic vinyl compounds and method for inhibiting the polymerization of the compounds

The invention provides a polymerization inhibitor which is easy of handling and little toxic and has high polymerization-inhibiting effect on aromatic vinyl compounds, and a method for inhibiting the polymerization of aromatic vinyl compounds. The invention relates to a polymerization inhibitor for aromatic vinyl compounds which comprises a specific quinonemethide compound and a specific organic sulfonic acid; and a method for inhibiting the polymerization of aromatic vinyl compounds by adding simultaneously a specific quinonemethide compound, a specific organic sulfonic acid, and, if necessary, a specific N-oxyl compound in the production, purification, or storage step of the vinyl compounds.

Patent FR2111325A5

Phenyl bisphenol derivative, preparation method and medical application thereof

本发明涉及苯双酚衍生物及其制备方法和在医药上的应用。本发明的苯双酚衍生物能够促进镇静催眠、脑保护，治疗和/或预防中枢神经系统相关的疾病。

Method for producing 2,3,5-trimethyl benzoquinone by oxidation of 2,3,6-trimethylphenol

The invention relates to a method for producing 2,3,5-trimethyl benzoquinone or a compound containing 2,3,5-trimethyl benzoquinone, the method comprising the following steps: Oxidation of 2,3,6-trimethylphenol with oxygen or an oxygen-containing gas in a two-or multi-phase reaction medium in the presence of a catalyst or catalyst system containing at least one copper (ll)-halide to a mixture containing 2,3,5-trimethyl benzoquinone, characterized in that the reaction medium contains water and at least one secondary aliphatic acyclic alcohol having 6 or more, preferably 7 or more, carbon atoms.

Patent SU425386A3

A kind of novel anode material, preparation method and applications

本发明公开了一种新型正极材料2,2’‑(1,4‑苯醌)、该正极材料的制备方法及其在锂离子电池中的应用，2,2’‑(1,4‑苯醌)是以2,2',5,5'‑四甲氧基联苯为原料，经氧化反应获得。本发明提供一种高比容量(501mAh·g ‑1 )有机小分子二聚体正极材料并使之应用在锂离子电池中，利于提升锂离子电池的能量密度，并进一步降低锂离子电池的生产成本。

Manufacture of polycyclic substituted quinones

2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione as a cancer therapeutic

2-Dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione (DMDD), as well as variants, derivatives, analogs, modifications, and conjugates thereof, are identified as therapeutic agents for treating or preventing human cancers and precancerous conditions. DMDD can be isolated from the root of Averrhoa carambola L. , commonly known as starfruit. Pharmaceutical and nutraceutical compositions, as well as dietary supplements, are provided, as are methods of administration and treatment.

Photo-thermally induced polymerization inhibitors for electrophoretic media

一種可被加入電泳顯示器之電泳介質包括分散液，其可被容納於複數個微囊或微胞、或聚合連續相中。該分散液可包括非極性流體、複數個第一帶電粒子、及抑制該粒子及/或微胞或聚合連續相之間的潛在交聯之光熱引發聚合抑制劑。該抑制劑可為具有不飽和烴環，及羥基、羰基、與亞硝基至少之一的化合物。該複數個微胞或聚合連續相及粒子塗層可包括含有(甲基)丙烯酸酯之聚合材料。

Charge storage material, electrode active material and secondary battery

Materials having charge-storing properties and made variously of dipyridine-fused benzoquinones of formula (1) below or derivatives thereof, dipyridine-fused benzoquinones of formula (4) below or derivatives thereof, or dipyridine-fused benzoquinone skeleton-containing polymers are provided. In the formulas, Ar 1 and Ar 2 are each independently a pyridine ring that forms together with two carbon atoms on a benzoquinone skeleton, or a derivative thereof. When used as electrode active materials, these charge storage materials are capable of providing high-performance batteries possessing a high capacity, high rate characteristics and high cycle characteristics.

Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

Catalytic oxidation of hydroxy containing aromatic compounds

The present invention relates to a process for the catalytic oxidation of hydroxy containing aromatic compounds to form the respective quinone compounds comprising contacting a hydroxy containing aromatic compound of the formula: (see fig. I) with a molecular oxygen containing gas in the presence of: (a) a catalytic amount of a cobalt (II) compound, (b) a primary aliphatic amine having the nitrogen atom attached to a tertiary carbon, and (c) an alcohol selected from the group consisting of methyl alcohol, ethyl alcohol, isopropyl alcohol, butyl alcohol, 2,2,2-trifluoroethanol and benzyl alcohol, wherein X is selected from the group consisting of -OH, or (see fig. II) and R is individually selected from the group of radicals consisting of hydrogen, an alkyl having from about 1 to about 18 carbon atoms, an alkoxy having from about 1 to 8 carbon atoms, a phenyl and an aralkyl having 7 to 12 carbon atoms.

Novel cannabigerol derivatives.

La presente invención se refiere a nuevos derivados de quinona de cannabigerol de fórmula (I) en la que R es el átomo de carbono de un grupo lineal o ramificado representado por: grupos arilo, alquenilo, alquinilo o alcoxicarbonilo; o en la que R es el átomo de nitrógeno de un grupo lineal o ramificado, representado por: grupos de alquilamino, arilamino, alquenilamino o alquinilamino; o, como alternativa, R representa un enlace entre 2 moléculas de fórmula (I) que forman un dímero. La invención también se refiere al uso de cualquiera de los compuestos de Fórmula (i) como medicamentos en terapia, particularmente para tratar enfermedades relacionadas con PPARg debido a su alto efecto agonista de PPARg que carece de actividades electrófilas (activación de Nrf2) y citotóxicas. La presente invención 15 también proporciona composiciones farmacéuticas que comprenden dichos compuestos y método para tratar enfermedades con dichos compuestos.

Pure 1-nitroanthraquinone (derivs) prodn - by nitrating anthraquinone (derivs) in hydrofluoric acid, for use in dye mfr

1-Nitroanthraquinone or its derivs. are produced by nitrating anthraquinone or its derivs. with a nitrating agent in hydrofluoric acid (contg. 5-30% of water, pref. 10-20%) at 10-50 degrees C (pref. 30-40 degrees C). 1-nitroanthraquinone and its methyl-, chloro-, bromo-, hydroxy- or carboxylic acid derivs., can be used in the mfr. of 1-aminoanthraquinone and its derivs. for use in the dye industry. Pure mono-nitrated prods are pptd. and can be easily sepd. by filtration, whilst the unreacted anthraquinone or its derivs. and by-prods (formed in small quantity) remain in the mother liquor which can be recycled after replenishment with HF. The nitrating agent can be a HNO3-H2SO4 mixt. (80-20 to 20:80), NO2 or N2O4; conc. HNO3 contg. up to 10% of H2SO4 or H3PO4 can also be used.

Method of stabilizing perfluorodioxolane compound, perfluorodioxolane compound-containing composition and method of producing perfluorodioxolane compound polymer

Provided is a method of stabilizing a perfluorodioxolane compound, which includes having a quinone compound present in a composition containing a perfluorodioxolane compound, wherein the perfluorodioxolane compound is one or more perfluorodioxolane compounds selected from the group consisting of a perfluorodioxolane compound denoted by general formula (1) and a perfluorodioxolane compound denoted by general formula (2).

Process for the stabilization of aldehydes, ethers, fatty oils, vegetable oils, lubricating oils or petroleum hydrocarbons against oxidation, peroxidation and polymerization

Method for the preparation of 2,3,5-trimethylbenzoquinone

New process for the preparation of organic compounds from complex organometallic compounds and resulting products

The inhibitor for the polymerization that photo-thermal for electrophoretic medium induces

可被掺入到电泳显示器中的电泳介质包括可以包含在多个微囊或微单元或聚合物连续相中的分散液。所述分散液可包括非极性流体、多个第一带电粒子；和光热诱导的聚合的抑制剂，所述抑制剂抑制粒子和/或微单元或聚合物连续相之间的潜在交联。所述抑制剂可以是具有不饱和烃环和羟基基团、羰基基团和亚硝基基团中的至少一种的化合物。多个微单元或聚合物连续相和粒子的涂层可包含含有(甲基)丙烯酸酯的聚合物材料。

Patent JPS6255650B2

PROCEDURE FOR THE PREPARATION OF ADDICTS, CHELATES OR COMPLEXES OF ANIONS AND KETOCOMPOSTS.

COMPUESTOS CETONICOS CON UN CARBURO CONTIGUO AL GRUPO CETONICO, LIGADO A UN SUSBTITUYENTE QUE ATRE FUERTEMENTE LOS ELECTRONES, Y CONJUGADO CON EL GRUPO CETONICO POR ORBITALES (PI) DE ELECTRONES. LOS COMPUESTOS CETONICOS TIENEN LA CAPACIDAD DE MOSTRAR A LOS ANIONES DE LOS AXACIDOS EN ACCION RECIPROCA POR LO QUE SE CONFORMAN CONDUCTOS QUELATOS Y COMPLEJOS. CUANDO EN EL COMPUESTO CETONICO TIENE PARTE DE UNOS CROMOFEROS SE PRESENTA EN LA FORMACION DE ADUCTOS CON LOS ANIONES DEL OXACIDO UN DESPLAZAMIENTO DE LA ABSORCION EN LA ZONA DE UNA VISIBLE O ULTRAVIOLETA. LOS COMPONENTES DETONICOS CORRESPONDIENTES PUEDEN SERVIR PARA PROBAR LA LOS ANIONES DE LOS OXACIDOS COMO COMPONENTES SENSIBLES DE IONES O COMO INDICADORES DE COLOR. KETONE COMPOUNDS WITH A CARBIDE CONTIGUOUS TO THE KETONE GROUP, LINKED TO A SUBSTITUTE THAT STRONGLY ATTRACT ELECTRONS, AND CONJUGATED TO THE KETONE GROUP BY ORBITALS (PI) OF ELECTRONS. THE KETONIC COMPOUNDS HAVE THE CAPACITY TO SHOW THE ANIONS OF THE AXACIDS IN RECIPROCAL ACTION, SO THEY FORM CHELATE AND COMPLEX CONDUITS. WHEN THE KETONIC COMPOUND HAS PART OF SOME CHROMOFERS, IT IS PRESENTED IN THE FORMATION OF ADDUCT WITH THE ANIONS OF THE OXACID, A DISPLACEMENT OF THE ABSORPTION IN THE AREA OF A VISIBLE OR ULTRAVIOLET. THE CORRESPONDING DETONIC COMPONENTS CAN BE USED TO TEST THE ANIONS OF THE OXACIDES AS ION-SENSITIVE COMPONENTS OR AS COLOR INDICATORS.

Process for the oxidation or reduction of organic compounds

PROCESS FOR PREPARING CONDENSATION PRODUCTS FROM ALKYLPHENOLS, ALCOXYPHENOLS AND 1-NAPHTOLS

Organo-metallo-carbonyl complexes prepared by the reaction of acetylene with a metalcarbonyl